

## Promacta Kit - (12 mg/packet and 25 mg/packet ; Oral Suspension)

<b>Generic Name</b>	Eltrombopag Olamine	<b>Innovator</b>	Novartis
<b>Dosage</b>	12 mg/packet and 25 mg/packet ; Oral Suspension	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	None
<b>Indication</b>	PROMACTA is a thrombopoietin receptor agonist indicated for the treatment of: 1) thrombocytopenia in adult and pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy 2) thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy 3) patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.